Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 21
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Daily Lipolysis Gene Expression in Male Rat Mesenteric Adipose Tissue: Obesity and Melatonin Effects

  • Cano Barquilla, María Pilar
  • Jiménez Ortega, Vanesa
  • Fernández Mateos, María Del Pilar
  • Virto Ruiz, Leire
  • Maldonado Bautista, Estela
  • Pérez De Miguelsanz, María Juliana
  • Esquifino Parras, Ana Isabel
Melatonin is involved in various functions such as the timing of circadian rhythms, energy metabolism, and body mass gain in experimental animals. However, its effects on adipose tissue lipid metabolism are still unclear. This study analyzes the effects of melatonin on the relative gene expression of lipolytic proteins in rat mesenteric adipose tissue and free fatty acid (FFA) and glycerol plasma levels of male Wistar rats fed a high-fat (HFD) or maintenance diet. Four experimental groups were established: control, obese, and control or obese plus 2.3 mg/kg/day of melatonin in tap water. After 11 weeks, animals were sacrificed at different times throughout a 24 h cycle, and mesenteric adipose tissue and plasma samples were collected and analyzed. Cgi58, Perilipin, and Dgat1 gene expression, as well as FFA and glycerol concentrations, showed rhythm patterns in the control group. HFD disrupted those rhythm patterns and increased FFA and glycerol concentrations during the dark photoperiod. In both melatonin-treated groups, almost all analyzed genes showed circadian patterns. Notably, melatonin significantly prevented the increase in FFA levels during the dark photoperiod in obese rats (obese group: ~1100 mM vs. obese + melatonin group: ~600 μM, similar to control levels). However, the rhythmic pattern observed in control animals was not sustained. According to our results, melatonin could regulate circadian gene transcription of mesenteric adipose tissue lipolysis proteins. The effect of melatonin on preventing elevated FFA plasma levels associated with high-fat diet intake warrants further investigation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Methylxanthines for halogen bonded cocrystals with 1,4-diiodotetrafluorobenzene, green synthesis, structure, photophysics and DFT studies

  • Benito, Mónica|||0000-0001-5550-4757
  • Núñez, Rosario|||0000-0003-4582-5148
  • Sinha, Sohini|||0000-0003-0875-5080
  • Roscini, Claudio|||0000-0002-0157-8934
  • Hidalgo-Rosa, Yoan
  • Schott, Eduardo
  • Zarate, Ximena
  • Molins Grau, Elies|||0000-0003-1012-0551
Four new halogen-bonded cocrystals of biological methylxanthines, named caffeine, theophylline and theobromine, have been prepared with 1,4-diiodotetrafluorobenzene as a halogen bond donor by mechanochemical and solution processes. For theophylline, N⋯I and N⋯O interactions were observed, while for caffeine and theobromine, only N⋯I was detected. The solids were characterized by PXRD, SC-XRD, FTIR and thermal methods (TGA-DSC analyses). In addition, the solid-state photoluminescence properties of the methylxanthines and their respective cocrystals have been studied and quantum chemistry calculations have been performed to rationalise and understand the electronic and optical properties of all compounds. This work provides a triad of natural methylxanthines capable of forming halogen-bonded multicomponent systems that can give rise to a cocrystal-to-crystal transformation with off-on luminescence activation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Multifunctional self-refrigerated multivariate {GdLn} (Ln = Dy, Tb, Tb/Eu) metal-organic frameworks

  • Li, Zhen|||0000-0002-8497-7497
  • Arauzo, Ana|||0000-0002-5999-341X
  • Roscini, Claudio|||0000-0002-0157-8934
  • Giner Planas, José|||0000-0002-1648-2169
  • Bartolome, Elena|||0000-0001-5108-0977
Multivariate metal-organic frameworks (MOFs) containing multiple lanthanide ions present a compelling avenue for developing versatile materials with tailored properties. In this work, we synthesized "self-refrigerated" multifunctional carborane-based MOFs of formula unit {[(GdLn)(mCB-L)(NO)(DMF)]·Solv} strategically combining Gd ions, known for their ability to achieve large magnetocaloric effects (MCE), with various lanthanides (Ln = Dy, Tb, Eu, Tb/Eu) intended to act as Single Molecule Magnet (SMM) or/and luminescent units. The intricate magnetic, thermal, and optical properties of these multivariate Ln-MOFs were unraveled through a comprehensive characterization employing dc and ac magnetometry, X-ray Absorption Spectroscopy (XAS), X-ray Magnetic Circular Dichroism (XMCD), and luminescence measurements. Element-selective XAS-XMCD technique proved instrumental in elucidating the magnetic properties of the individual lanthanides, and their contribution to the macroscopic properties of the MOFs. We demonstrate that GdLn (Ln = Tb, Dy) MOFs exhibit multifunctionality, incorporating MCE, field-induced magnetic relaxation dominated by the anisotropic ion, and green emission for Ln = Tb. Conversely, GdLn (Ln = Eu, Eu/Tb) MOFs display MCE, field-induced SMM behavior associated with Gd, and red/yellow luminescent emission for Ln = Eu and Eu/Tb substitutions, respectively. Our findings significantly contribute to our understanding of "complex magnetic molecular materials" and set a pathway for the design of multifunctional multi-lanthanide MOFs endowed with tailored properties for various technological applications.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Fluorescent molecular systems based on carborane-perylenediimide conjugates

  • Rodriguez-Madrid, Ruben|||0000-0002-9774-6655
  • Sinha, Sohini|||0000-0003-0875-5080
  • Parejo Bruque, Laura
  • Hernando, Jordi|||0000-0002-1126-4138
  • Núñez, Rosario|||0000-0003-4582-5148
This study presents the successful synthesis of two perylenediimide (PDI)-based ortho-carborane (o-carborane) derivatives, PDI-CB1 and PDI-CB2, through the insertion of decaborane into alkyne-terminated PDIs (PDI1 and PDI2). The introduction of o-carborane groups did not alter the optical properties of the PDI units in solution compared to their carborane-free counterparts, maintaining excellent fluorescence quantum yields of around 100% in various solvents. This was achieved by using a methylene linker to minimize electronic interaction between PDI and o-carborane, and by incorporating bulky o-carborane groups at imide- position to enhance solubility and prevent π-π stacking-induced aggregation. Aggregation studies demonstrated that PDI-CB1 and PDI-CB2 have greater solubility than PDI1 and PDI2 in both nonpolar and aqueous solvents. Despite the steric hindrance imparted by the o-carborane units, the solid state emission of PDI-CB1 and PDI-CB2 was affected by aggregation-caused fluorescence quenching. However, solid PDI-CB1 preserved bright red excimer-type emission, which persisted in water-dispersible nanoparticles, indicating potential for application as a theranostic agent combining fluorescence bioimaging with anticancer boron neutron capture therapy (BNCT) due to its high boron content.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Correction, ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer (BMC Cancer, (2024), 24, 1, (876), 10.1186/s12885-024-12501-5)

  • Leary, Alexandra
  • Estévez-García, Purificación
  • Sabatier, Renaud
  • Ray-Coquard, Isabelle|||0000-0003-2472-8306
  • Romeo, Margarita|||0000-0003-1725-8115
  • Barretina-Ginesta, Maria-Pilar|||0000-0003-0074-6614
  • Gil-Martin, Marta|||0000-0002-8548-5355
  • Garralda, Elena|||0000-0002-4412-7842
  • Bosch-Barrera, J.|||0000-0002-0893-7821
  • Morán, Teresa
  • Martin-Martorell, Paloma
  • Nadal, Ernest|||0000-0002-9674-5554
  • Gascón, Pere|||0000-0001-9690-9873
  • Rodon Ahnert, Jordi|||0000-0001-6467-3632
  • Lizcano de Vega, José Miguel|||0000-0002-3154-5383
  • Muñoz-Guardiola, Pau|||0000-0002-0741-4463
  • Fierro-Durán, Gemma
  • Pedrós-Gámez, Oriol
  • Pérez-Montoyo, Hector
  • Yeste-Velasco, Marc|||0000-0001-7788-0913
  • Cortal, Marc
  • Perez Campos, Antonio
  • Alfón, José|||0000-0002-1874-0184
  • Domenech, Carles|||0000-0002-2817-3750
  • Pérez-Fidalgo, Alejandro
  • Oaknin, Ana|||0000-0002-3592-7194
Following publication of the original article [1], the authors reported the the equal contribution statement was missing in the original submission. The correct equal contribution statement is: Alejandro Pérez-Fidalgo and Ana Oaknin contributed equally to this work.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer

  • Leary, Alexandra
  • Estévez-García, Purificación
  • Sabatier, Renaud
  • Ray-Coquard, Isabelle|||0000-0003-2472-8306
  • Romeo, Margarita|||0000-0003-1725-8115
  • Barretina-Ginesta, Maria-Pilar|||0000-0003-0074-6614
  • Gil-Martin, Marta|||0000-0002-8548-5355
  • Garralda, Elena|||0000-0002-4412-7842
  • Bosch-Barrera, J.|||0000-0002-0893-7821
  • Morán, Teresa
  • Martin-Martorell, Paloma
  • Nadal, Ernest|||0000-0002-9674-5554
  • Gascón, Pere|||0000-0001-9690-9873
  • Rodon Ahnert, Jordi|||0000-0001-6467-3632
  • Lizcano de Vega, José Miguel|||0000-0002-3154-5383
  • Muñoz-Guardiola, Pau|||0000-0002-0741-4463
  • Fierro-Durán, Gemma
  • Pedrós-Gámez, Oriol
  • Pérez-Montoyo, Hector
  • Yeste-Velasco, Marc|||0000-0001-7788-0913
  • Cortal, Marc
  • Perez Campos, Antonio
  • Alfón, José|||0000-0002-1874-0184
  • Domenech, Carles|||0000-0002-2817-3750
  • Pérez-Fidalgo, Alejandro
  • Oaknin, Ana|||0000-0002-3592-7194
Background: Carboplatin and paclitaxel (CP) have been the standard of care for advanced/recurrent endometrial cancer (EC) for many years. However, this chemotherapy combination shows limited efficacy and recurrences often occur in less than 12 months. ABTL0812 is a novel drug that selectively kill cancer cells by cytotoxic autophagy and has shown anticancer efficacy in preclinical models of EC in combination with CP. Methods: ENDOLUNG was an open-label, phase 1/2 clinical trial designed to determine the safety and efficacy of Ibrilatazar (ABTL0812) with CP in patients with advanced/recurrent EC and non-irradiable stage III and IV squamous non-small cell lung cancer (sq-NSCLC). The phase 1 part consisted of a 3 + 3 de-escalation design followed by an expansion cohort with 12 patients. The primary endpoint was safety. ABTL0812 starting dose was 1300 mg tid combined with carboplatin at area under the curve (AUC) 5 and paclitaxel at 175 mg/m both administered every 21 days for up to 8 cycles. The phase 2 part included a total of 51 patients. The primary endpoint was overall response rate (ORR) and the secondary endpoints included duration of response (DOR), progression-free survival (PFS) and overall survival (OS). Results: During the phase 1 only one dose limiting toxicity (DLT), a grade 4 neutropenia, was observed in 1 out of 6 patients, thus no de-escalation was applied. One additional DLT, a grade 3 febrile neutropenia, was observed in the expansion cohort, thus the recommended phase 2 dose (RP2D) for ABTL0812 was established at 1300 mg tid. Most frequent hematological adverse events (AE) of the combination were neutropenia (52.9%), anemia (37.3%) and thrombocytopenia (19.6%). Nausea (66.7%), asthenia (66.7%), diarrhea (54.9%) and vomiting (54.9%) were the most frequent non-hematological adverse events (AEs). The combination of ABTL0812 plus CP showed an ORR of 65.8% (13.2% complete response and 52.6% partial response) with a median DOR of 7.4 months (95% CI: 6.3-10.8 months). Median PFS was 9.8 months (95% CI: 6.6-10.6) and median OS 23.6 months (95% CI 6.4-ND). Pharmacokinetic parameters were compatible with target engagement observed in preclinical studies, and blood pharmacodynamic biomarkers indicated sustained target regulation during, at least, 28 days after starting the treatment. Conclusions: This study suggests that the combination of ABTL0812 with CP is safe and feasible with an encouraging activity in patients with advanced/recurrent EC. Our data warrant further confirmation in prospective randomized trials. Trial registration: EU Clinical Trial Register, EudraCT number 2016-001352-21 and National Clinical Trials Number, NCT03366480. Registration on 19 September 2016.
Repisalud
Publicación Artículo científico (JournalArticle)

Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: a meta-analysis

  • Garcia-Alvarez, Monica
  • Jimenez-Sousa, Maria Angeles
  • Fernandez-Rodriguez, Amanda
  • Guzman-Fulgencio, Maria
  • Resino, Salvador
There is growing evidence that vitamin D is related to chronic hepatitis C (CHC) pathogenicity. We analyzed the relationship of vitamin D status with advanced liver fibrosis (ALF) in CHC treatment-naïve patients and sustained virologic response (SVR) in CHC patients on pegylated interferon alpha plus ribavirin (pegIFNα/ribavirin) therapy. We performed a meta-analysis of all eligible studies published to date (April, 2014) in PubMed, SCOPUS, LILACS, and the Cochrane Library, assessing plasma/serum vitamin D levels related to ALF and/or SVR. Pooled odds ratios (ORs) were estimated by either fixed or random effects models. Fourteen studies were selected from the literature search, seven for ALF (1,083 patients) and 11 for SVR (2,672 patients). For liver fibrosis, low vitamin D status was related to a diagnosis of ALF, with the cutoffs of 10 ng/mL (OR=2.37, 95% confidence interval [CI]=1.20, 4.72) and 30 ng/mL (OR=2.22, 95% CI=1.24, 3.97) being significant, and a near-significance for 20 ng/mL (OR=1.44, 95% CI=0.99, 2.12). Regarding SVR, a significant heterogeneity among studies was found (P<0.001), and we only found a significant association with SVR for a vitamin D cutoff of 20 ng/mL (OR=0.53, 95% CI=0.31, 0.91). When meta-analysis was performed excluding the outliers, significant pooled ORs were found for all patients (10 ng/mL [OR=0.48, 95% CI=0.34, 0.67] and 20 ng/mL [OR=0.58, 95% CI=0.45, 0.76]) and GT1/4 patients (10 ng/mL [OR=0.53, 95% CI=0.34, 0.81] and 20 ng/mL [OR=0.54, 95% CI=0.39, 0.74]). Conclusion: Low vitamin D status in CHC patients is associated with a higher likelihood of having ALF and lower odds of achieving SVR following pegIFNα/ribavirin therapy.
Repisalud
Publicación Artículo científico (JournalArticle)

Toll-like receptor 8 (TLR8) polymorphisms are associated with non-progression of chronic hepatitis C in HIV/HCV coinfected patients

  • Fernandez-Rodriguez, Amanda
  • Berenguer, Juan
  • Jimenez-Sousa, Maria Angeles
  • Garcia-Alvarez, Monica
  • Aldámiz-Echevarria, Teresa
  • Pineda-Tenor, Daniel
  • Díez, Cristina
  • De la Barrera, Jorge
  • Bellón, José María
  • Briz, Veronica
  • Resino, Salvador
Toll-like receptor 8 (TLR8) polymorphisms have been related to hepatitis C virus (HCV) infection. The aim was to estimate the association of TLR8 polymorphisms with HCV-related outcomes in HIV/HCV coinfected patients. We performed a cross-sectional study of 220 patients who underwent a liver biopsy. TLR8 polymorphisms were genotyped using GoldenGate® assay. The outcome variables were non-fibrosis (F0), mild-inflammation (A0/A1), and non-steatosis [fatty hepatocytes (FH) <10%]. Logistic regression analysis was used to compare the outcome variables according to TLR8 polymorphisms. Four polymorphisms were analyzed (rs1013151, rs5744069, rs17256081 and rs3764880rs1013151). Female patients had higher frequency of TLR8 major alleles at rs17256081 and rs101315, and minor alleles at rs3764880 and rs5744069. Male patients had higher frequency of TLR8 minor alleles except for rs3764880, where major alleles were higher (p<0.01). Two TLR8 polymorphisms (rs1013151 and rs5744069) were significantly associated with non-fibrosis (F0) [adjusted odds ratio (aOR)=4.42 (95% of confidence interval (95%CI)=1.54; 12.68) (p=0.006) and aOR=4.76 (95%CI=1.69; 13.37) (p=0.003); respectively]. When data were stratified by gender, rs1013151 and rs5744069 polymorphisms remained significant for male patients [adjusted odds ratio (aOR)=4.49 (95%CI=1.08; 18.62) (p=0.039) and aOR=6.17 (95%CI=1.45; 26.20) (p=0.014); respectively]. When data were stratified by major HCV genotypes, patients infected with HCV genotype 1 (GT1) had significant values for both rs1013151 and rs5744069 polymorphisms [aOR=5.79 (95%CI=1.44; 23.32) (p=0.013) and aOR=8.01 (95%CI=2.16; 35.65) (p=0.005); respectively]. Finally, none of the TLR8 polymorphisms were significantly associated with mild-inflammation or non-steatosis. In conclusion, TLR8 polymorphisms seem to be related to non-progression of liver fibrosis in HIV/HCV coinfected patients, particularly in males and those patients infected with GT1.
Repisalud
Publicación Artículo científico (JournalArticle)

Mx1, OAS1 and OAS2 polymorphisms are associated with the severity of liver disease in HIV/HCV-coinfected patients: A cross-sectional study

  • Garcia-Alvarez, Monica
  • Berenguer, Juan
  • Jimenez-Sousa, Maria Angeles
  • Pineda-Tenor, Daniel
  • Aldámiz-Echevarria, Teresa
  • Tejerina, Francisco
  • Díez, Cristina
  • Vázquez-Morón, Sonia
  • Resino, Salvador
The mechanisms involved in the chronic hepatitis C progression are incompletely understood. The aim was to analyze the association between 2'5'oligoadenylate synthetase 1,2 and 3 (OAS1-3) and myxovirus resistance proteins 1 (Mx1) polymorphisms and severity of liver disease in human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfected patients. We performed a cross-sectional study in 219 patients that underwent a liver biopsy. DNA genotyping for Mx1 (rs469390), OAS1 (rs2285934), OAS2 (rs1293762) and OAS3 (rs2010604) was performed by using GoldenGate assay. The outcome variables ion liver biopsy were: (i) significant fibrosis (F ≥ 2); (ii) moderate activity grade (A ≥ 2). Additive model of inheritance for genetic association test was used. The likelihood of having significant fibrosis (F ≥ 2) was lower in patients carrying OAS2 rs1293762 A allele [adjusted odds ratio (aOR) = 0.51; p = 0.040]. Besides, the likelihood of having moderate activity grade (A ≥ 2) was higher in patients carrying Mx1 rs464397 C allele (aOR = 1.63; p = 0.028) and Mx1 rs469390 G allele (aOR = 1.97; p = 0.005), while it was lower in patients carrying OAS1 rs2285934 A allele (aOR = 0.64; p = 0.039) and OAS2 rs1293762 A allele (aOR = 0.41; p = 0.009). In conclusion, Mx1 and OAS1-2 polymorphisms were associated with the severity of liver disease in HIV/HCV-coinfected patients, suggesting a significant role in the progression of hepatic fibrosis.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Nuevas herramientas para la mejora de la ergonomía en el sector de la Construcción, New tools for the ergonomics in the construction sector

  • Piedrabuena Cuesta, Alicia
  • Castelló Mercé, Purificación
  • Ferreras Remesal, Alberto
  • Oltra Pastor, Alfonso
  • Santander Iñigo, Antonio
  • Cortés Jiménez, Balbino
  • Rosel Ajamil, Luis
  • Ruiz Folgado, Raquel
[EN] The Instituto de Biomecánica de Valencia(IBV) and the Fundación Laboral de la Construcción (FLC) are carrying out projects in the field of the ergonomics applied to the Construction sector since seven years ago. These projects have produced a set of pioneer materials, which have covered a series of existing lacks on the subject of ergonomics; also, these materials have supposed a help for the professionals of this sector. In this article, are presented the results obtained in the projects that have developed during the year 2012., [ES] El Instituto de Biomecánica (IBV) y la Fundación Laboral de la Construcción (FLC) llevan siete años realizando proyectos en el ámbito de la ergonomía aplicados al sector de la construcción. Estos proyectos han dado como fruto un conjunto de materiales, pioneros en el sector, que han cubierto una serie de carencias existentes en materia de ergonomía y han supuesto una ayuda para los profesionales del mismo. En este artículo se presentan los resultados obtenidos en los proyectos desarrollados durante el año 2012., Los tres proyectos han sido desarrollados con la finaciación de la Fundación para la Prevención de Riesgos Laborales (Convocatoria de asignación de recursos del ejercicio 2011): - Ergonomía en la construcción. Recursos para el formador. Fase II (IS-0020/2011) - Ampliación del manujal de ergonomía en la construcción. Fase III. (IS-0033/2011) - Ergonomía activa para la prevención de TME en el secor de la construcción. (IS-0044/2011)
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Enhancing the Antimicrobial Photodynamic Activity of Heteroleptic Ruthenium(II) Complexes: Role of Asymmetric N-Donor-Based Ligands

  • Mesra-Brahmi, Abir
  • Martínez-Olmo, Sofia
  • Guerrero Troyano, Isabel
  • Fontrodona, xavier
  • Poater, Jordi
  • Verdaguer, Ariadna
  • Auset, Maria
  • Bresolí-Obach, Roger
  • Nonell, Santi
  • Núñez, Rosario
  • Romero García, Isabel
With their highly stability and tunable photophysical properties, Ru(II) complexes are excellent photosensitizer candidates for antimicrobial photodynamic therapy (aPDT), offering selective bacterial targeting without driving resistance. A series of heteroleptic Ru(II) N-donor complexes, incorporating symmetric N-bidentate ligands such as 1,10-phenanthroline and 4,4′-diphenyl-2,2′-bipyridine, together with asymmetric N-bidentate ligands including pyridine–pyrazole, iminopyridines, and iminoquinoline, have been successfully synthesized to assess their potential as photosensitizers for aPDT. All Ru(II) complexes exhibited distorted octahedral coordination, unique ligand arrangements, and hydrophobicity, which influenced their electronic properties and photodynamic activity. TDDFT calculations reliably reproduced experimental trends. All complexes produce singlet oxygen and superoxide radical anion upon exposure to visible light and are capable of photoinactivating S. aureus bacteria at micromolar concentrations. Complex 2, containing two phenanthrolines and a pyridine–pyrazole ligand, displays the highest potential for aPDT due to its optimized ligand structure, which enhances its physicochemical and optical properties and singlet oxygen production. It penetrates the bacterial cytoplasm and damages genomic DNA, efficiently neutralizing both Gram-positive and Gram-negative strains, as well as Candida albicans yeasts to a lesser extent. Meanwhile, it shows no toxicity toward human fibroblasts within therapeutic dose ranges. By bridging the gap between molecular structure and biological function, these results establish novel design criteria for choosing ligands to develop effective, selective Ru(II) aPDT agents., info:eu-repo/semantics/publishedVersion
Helvia. Repositorio Institucional de la Universidad de Córdoba
Publicación Artículo científico (JournalArticle)

Assessing the diagnostic, prognostic, and therapeutic potential of the somatostatin/cortistatin system in glioblastoma

  • G‐García, Miguel E
  • De la Rosa Herencia, Ana de la Salud
  • Flores Martínez, Álvaro
  • Ortega-Bellido, María
  • Sánchez-Sánchez, Rafael
  • Blanco-Acevedo, Cristóbal
  • Gahete Ortiz, Manuel D.
  • Solivera, Juan
  • Luque, Raúl M.
  • Fuentes-Fayos, Antonio C.
Glioblastoma remains an incurable tumour (median survival: ~ 15 months) and little clinical progress has been made over the past decades. Therefore, identification of novel biomarkers and therapeutic targets is imperative. Targeting the somatostatin/cortistatin-system is considered a successful avenue for treating different tumour pathologies. Thus, we comprehensively characterized (clinically and molecularly) the expression of the somatostatin/cortistatin-system components [ligands and receptors (SSTRs)] using five cohorts of patients and tested the in-vitro therapeutic response of different SSTR-agonists and somatostatin analogs (SSAs) in primary patient-derived glioblastoma cells. A clear downregulation of the whole somatostatin/cortistatin-system (except for SSTR5) in glioblastoma vs. non-tumour brain samples was demonstrated, with high discriminatory capacity. Moreover, poor overall-survival and critical aggressiveness-parameters (i.e., recurrence, IDH1-wildtype and G-CIMP status, classical and mesenchymal GBM-subtypes, EGFR-amplification) were robustly associated with SSTR1/SSTR2 downregulation. Notably, octreotide, pasireotide, and SSTR1/2/5-agonists treatments significantly reduced cell-proliferation in primary patient-derived GBM-cells. Molecularly, antitumour effects of octreotide/pasireotide were exerted through key signalling-factors related to glioblastoma-aggressiveness (i.e., CDKN1A-B/JAK-STAT/NF-κB/TGF-β-pathways). Altogether, this study demonstrated that somatostatin/cortistatin-system is drastically altered in GBM representing a useful prognostic tool, and that SSTR-modulators might represent a potential therapeutic strategy to treat specific subsets of patients with GBM.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pseudokinases, Tribbles Proteins and Cancer

  • Velasco, Guillermo
  • Link, Wolfgang
The human kinome comprises 518 protein kinases, of which approximately 10% lack one or more of the conserved amino acids necessary for catalytic activity. These proteins are categorized as pseudokinases and are predicted to be inactive enzymatically [1]. Pseudokinases are believed to primarily signal via noncatalytic mechanisms, such as protein–protein interactions, contributing to the development of various human diseases. Recently, this class of kinase-like proteins has emerged as a promising target for drug development [2]. Several pseudokinases have been implicated in regulating signaling pathways involving receptor tyrosine kinases, LKB1/AMPK, AKT, MAPKs, and other pathways associated with cancer initiation and progression. Among them, the Tribbles family of pseudokinases, including TRIB1, TRIB2, and TRIB3, has garnered significant attention in the past decade due to their ability to modulate inflammation, metabolism, and cancer by controlling key signaling pathways [3]. In response to this intricate landscape, the goal of this Special Issue is to consolidate recent studies and discoveries that shed light on the molecular mechanisms of cell signaling mediated by Tribbles pseudokinases in cancer, aiming to conceptualize the available evidence. This Special Issue, titled “Pseudokinases, Tribbles Proteins, and Cancer,” encompasses six original articles, seven review articles, and one commentary, each advancing knowledge in this research field., This work was supported by the Spanish Ministry of Science, Innovation and Universities through Grant RTI2018-094629-B-I00 to WL. Tribbles-related work in GV laboratory was supported by the Instituto de Salud Carlos III (ISCIII) and confounded by the European Regional Development Fund (ERDF), “A way to make Europe”, grant number PI18/00442 integrated into the State Plan for R & D + I 2017-2020 and grant number PI21/00343 integrated into the State Plan for R & D + I 2021-2023, by the European Commission through the Horizon 2020 European Training Networks program, grant number H2020-MSCA-ITN-308 2016 721532; and by the Breast Cancer Now (formerly Breast Cancer Campaign) foundation, grant number 2012NovSP033., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Cut-offs and response criteria for the Hospital Universitario la Princesa Index (HUPI) and their comparison to widely-used indices of disease activity in rheumatoid arthritis

  • González-Álvaro, I.
  • Castrejón, I.
  • Ortiz, A.M.
  • Toledano, E.
  • Castañeda, S.
  • García-Vadillo, A.
  • Carmona, L.
  • Abasolo Alcazar, L.
  • Miguel, Alegre De
  • Andreu Sánchez, J.L.
  • Aragón Díez, A.
  • Balsa Criado, A.
  • Batlle Gualda, E.
  • Belmonte Serrano, M.A.
  • Beltrán Audera, J.
  • Beltrán Fabregat, J.
  • Bonilla Hernan, G.
  • Carmona Ortells, L.
  • Caro Fernández, N.
  • Casado, E.
  • Cebrian Mendez, L.
  • Corteguera Coro, M.
  • Cuadra Díaz, J.L.
  • Cuesta, E.
  • Fiter Aresté, J.
  • Freire Gonzalez, M.
  • Galindo Izquierdo, M.
  • García Meijide, J.A.
  • García Gómez, M.C.
  • Giménez Ubeda, E.
  • Gómez Centeno, E.
  • Gómez Vaquero, C.
  • González Fernández, M.J.
  • González Gómez, M.L.
  • González Hernández, T.
  • González-Alvaro, I.
  • González-Montagut Gómez, C.
  • Grandal Delgado, Y.
  • Gratacos Masmitja, J.
  • Hernández, Del R.
  • Instxaurbe, A.R.
  • Irigoyen Oyarzabal, M.V.
  • Jiménez Palop, M.
  • Juan Mas, A.
  • Júdez Navarro, E.
  • Larrosa Padro, M.
  • López Longo, F.J.
  • Loza Santamaria, E.
  • Maese Manzano, J.
  • Manero Ruiz, F.J.
  • Mateo Bernardo, I.
  • Mayordomo González, L.
  • Mazzucheli, R.
  • Medrano, San Idelfonso
  • Naranjo Hernández, A.
  • Pecondón Español, A.
  • Peiró Callizo, E.
  • Quirós Donate, J.
  • Ramos López, P.
  • Rivera Redondo, J.
  • Rodríguez Gómez, M.
  • Rodríguez López, M.
  • Roselló Pardo, R.
  • Sampedro Alvarez, J.
  • Sanmartí Sala, R.
  • Santos, Rey Rey
  • Tena Marsá, X.
  • Tenorio Martín, M.
  • Torres Martín, Mc
  • Ureña Garnica, I.
  • Diego, Valdazo De
  • Valls, M.
  • Villaverde García, V.
  • Zarco Montejo, P.
  • Zubieta Tabernero, J.
Objective To estimate cut-off points and to establish response criteria for the Hospital Universitario La Princesa Index (HUPI) in patients with chronic polyarthritis. Methods Two cohorts, one of early arthritis (Princesa Early Arthritis Register Longitudinal PEARL] study) and other of long-term rheumatoid arthritis (Estudio de la Morbilidad y Expresión Clínica de la Artritis Reumatoide EMECAR]) including altogether 1200 patients were used to determine cut-off values for remission, and for low, moderate and high activity through receiver operating curve (ROC) analysis. The areas under ROC (AUC) were compared to those of validated indexes (SDAI, CDAI, DAS28). ROC analysis was also applied to establish minimal and relevant clinical improvement for HUPI. Results The best cut-off points for HUPI are 2, 5 and 9, classifying RA activity as remission if =2, low disease activity if >2 and =5), moderate if >5 and <9 and high if =9. HUPI''s AUC to discriminate between low-moderate activity was 0.909 and between moderate-high activity 0.887. DAS28''s AUCs were 0.887 and 0.846, respectively; both indices had higher accuracy than SDAI (AUCs: 0.832 and 0.756) and CDAI (AUCs: 0.789 and 0.728). HUPI discriminates remission better than DAS28-ESR in early arthritis, but similarly to SDAI. The HUPI cut-off for minimal clinical improvement was established at 2 and for relevant clinical improvement at 4. Response criteria were established based on these cut-off values. Conclusions The cut-offs proposed for HUPI perform adequately in patients with either early or long term arthritis.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

The comparative responsiveness of Hospital Universitario Princesa Index and other composite indices for assessing rheumatoid arthritis activity

  • Gonzalez-Alvaro, I.
  • Castrejon, I.
  • Carmona, L.
  • Dougados, M.
  • Huizinga, T.
  • Abu Shakra, M.
  • Alberts, A.
  • Lopez, M.A.
  • Amital, H.
  • Aringer, M.
  • Aslanidis, S.
  • Berenbaum, F.
  • Bijlsma, H.
  • Garcia, F.J.B.
  • Bliddal, H.
  • Borofsky, M.
  • Brocq, O.
  • Buldakov, S.
  • Cantini, F.
  • Perez, L.C.
  • Chahade, W.
  • Ciconelli, R.
  • Codreanu, C.
  • Dahlqvist, S.R.
  • Damjanov, N.
  • Diamantopoulos, A.
  • Dimdina, L.
  • Dimic, A.
  • Dorokhov, A.
  • Dubikov, A.
  • Fadienko, G.
  • Fano, N.
  • Ferreira, G.
  • Gabrielli, A.
  • Gaffney, K.
  • Gaudin, P.
  • Gerlag, D.M.
  • Gerli, R.
  • Goncalves, C.R.
  • Hansen, M.S.
  • Hanvivadhanakul, P.
  • Hoili, C.
  • Hou, A.
  • Hunter, J.
  • Ilic, T.
  • Ionescu, R.
  • Kaine, J.
  • Kakurina, N.
  • Kamalova, R.
  • Kelly, T.
  • Knyazeva, L.
  • Krumina, L.
  • Kurthen, R.
  • Lagrone, R.P.
  • Lapadula, G.
  • Lavrentjevs, V.
  • Lawson, J.G.
  • Lazic, Z.
  • Lejnieks, A.
  • Levy, Y.
  • Lexberg, A.
  • Mader, R.
  • Mariette, X.
  • Markovits, D.
  • Mola, E.M.
  • Maugars, Y.
  • Guarch, J.M.
  • Mazurov, V.I.
  • Mikkelsen, K.
  • Vergles, J.M.
  • Nabizadeh, S.
  • Nanagara, R.
  • Nasonov, E.L.
  • Sarabia, F.N.
  • Neumann, T.
  • Novak, S.
  • Olech, E.
  • Oza, M.
  • Paran, D.
  • Parsik, E.
  • Pegram, S.
  • Suarez, M.P.
  • Popova, T.
  • Puechal, X.
  • Raja, N.
  • Ridley, D.
  • Rosner, I.
  • Rubbert-Roth, A.
  • Rudin, A.
  • Saraux, A.
  • Saulite-Kandevica, D.
  • Settas, L.
  • Sfikakis, P.
  • Sheeran, T.
  • Sizikov, A.
  • Stamenkovic, D.
  • Stefanovic, D.
  • Stolow, J.B.
  • Tan, A.L.
  • Tebib, J.
  • Tishler, M.
  • Tony, H.P.
  • Troum, O.M.
  • Uaratanawong, S.
  • Angulo, E.U.
  • Valenzuela, G.
  • van der Laken, K.
  • Van Laar, J.
  • van Riel, P.L.C.M.
  • Vasilopoulos, D.
  • Veldi, T.
  • Vinogradova, I.
  • Vosse, D.
  • Wassenberg, S.
  • Weidmann, C.
  • Weitz, M.
  • Wollenhaupt, J.
  • Xavier, R.
  • Yakupova, S.
  • Zagar, I.
  • Zavgorodnaja, T.
  • Zemerova, E.
  • Zisman, D.
  • Zonova, E.
  • Camona, L.
  • Alcazar, L.A.
  • de Miguel, C.A.
  • Sanchez, J.L.A.
  • Diez, A.A.
  • Criado, A.B.
  • Gualda, E.B.
  • Serrano, M.A.B.
  • Audera, J.B.
  • Fabregat, J.B.
  • Hernan, G.B.
  • Fernandez, N.C.
  • Casado, E.
  • Mendez, L.C.
  • Coro, M.C.
  • Diaz, J.L.C.
  • Cuesta, E.
  • Areste, J.F.
  • Gonzalez, M.F.
  • Izquierdo, M.G.
  • Meijide, J.A.G.
  • Gomez, M.C.G.
  • Ubeda, E.G.
  • Centeno, E.G.
  • Vaquero, C.G.
  • Fernandez, M.J.G.
  • Gomez, M.L.G.
  • Hernandez, T.G.
  • Gonzalez-Alvaro, I.
  • Gomez, C.G.M.
  • Delgado, Y.G.
  • Masmitja, J.G.
  • del Rio, A.H.
  • Instxaurbe, A.R.
  • Oyarzabal, M.V.I.
  • Palop, J.
  • Mas, A.J.
  • Navarro, E.J.
  • Padro, M.L.
  • Longo, F.J.L.
  • Santamaria, E.L.
  • Manzano, J.M.
  • Ruiz, F.J.M.
  • Bernardo, I.M.
  • Gonzalez, L.M.
  • Mazzucheli, R.
  • Medrano San Idelfonso, M.
  • Hernandez, A.N.
  • Espanol, A.P.
  • Callizo, E.P.
  • Donate, J.Q.
  • Lopez, P.R.
  • Redondo, J.R.
  • Gomez, M.R.
  • Lopez, M.R.
  • Pardo, R.R.
  • Alvarez, J.S.
  • Sala, R.S.
  • Rey, J.S.R.
  • Marsa, X.T.
  • Martin, M.T.
  • Martin, M.C.T.
  • Garnica, I.U.
  • de Diego, J.P.V.
  • Valls, M.
  • Garcia, V.V.
  • Montejo, P.Z.
  • Tabernero, J.Z.
  • Balsa, A.
  • Sanmarti, R.
  • Cabezas, J.A.
  • Cantalejo, M.
  • Chamizo, E.
  • Ciruelo, E.
  • Corrales, A.
  • Cruz, A.
  • Diaz, C.
  • Fiter, J.
  • Freire, M.M.
  • Galindo, M.
  • de Vicuna, M.R.G.
  • Gelman, S.M.
  • Crespo, R.G.
  • Fernandez, C.G.
  • Fernandez, M.J.G.
  • Hernandez, T.G.
  • Gracia, A.
  • Granados, J.
Objective To evaluate the responsiveness in terms of correlation of the Hospital Universitario La Princesa Index (HUPI) comparatively to the traditional composite indices used to assess disease activity in rheumatoid arthritis (RA), and to compare the performance of HUPI-based response criteria with that of the EULAR response criteria. Methods Secondary data analysis from the following studies: ACT-RAY (clinical trial), PROAR (early RA cohort) and EMECAR (pre-biologic era long term RA cohort). Responsiveness was evaluated by: 1) comparing change from baseline (Delta) of HUPI with Delta in other scores by calculating correlation coefficients; 2) calculating standardised effect sizes. The accuracy of response by HUPI and by EULAR criteria was analyzed using linear regressions in which the dependent variable was change in global assessment by physician (Delta GDA-Phy). Results Delta HUPI correlation with change in all other indices ranged from 0.387 to 0.791); HUPI's standardized effect size was larger than those from the other indices in each database used. In ACT-RAY, depending on visit, between 65 and 80% of patients were equally classified by HUPI and EULAR response criteria. However, HUPI criteria were slightly more stringent, with higher percentage of patients classified as non-responder, especially at early visits. HUPI response criteria showed a slightly higher accuracy than EULAR response criteria when using Delta GDA-Phy as gold standard. Conclusion HUPI shows good responsiveness in terms of correlation in each studied scenario (clinical trial, early RA cohort, and established RA cohort). Response criteria by HUPI seem more stringent than EULAR''s.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Enhancing the Antimicrobial Photodynamic Activity of Heteroleptic Ruthenium(II) Complexes: Role of Asymmetric N-Donor-Based Ligands

  • Mesra-Brahmi, Abir
  • Martínez-Olmo, Sofia
  • Guerrero Troyano, Isabel
  • Fontrodona, xavier
  • Poater, Jordi
  • Verdaguer, Ariadna
  • Auset, Maria
  • Bresolí-Obach, Roger
  • Nonell, Santi
  • Núñez, Rosario
  • Romero García, Isabel
With their highly stability and tunable photophysical properties, Ru(II) complexes are excellent photosensitizer candidates for antimicrobial photodynamic therapy (aPDT), offering selective bacterial targeting without driving resistance. A series of heteroleptic Ru(II) N-donor complexes, incorporating symmetric N-bidentate ligands such as 1,10-phenanthroline and 4,4′-diphenyl-2,2′-bipyridine, together with asymmetric N-bidentate ligands including pyridine–pyrazole, iminopyridines, and iminoquinoline, have been successfully synthesized to assess their potential as photosensitizers for aPDT. All Ru(II) complexes exhibited distorted octahedral coordination, unique ligand arrangements, and hydrophobicity, which influenced their electronic properties and photodynamic activity. TDDFT calculations reliably reproduced experimental trends. All complexes produce singlet oxygen and superoxide radical anion upon exposure to visible light and are capable of photoinactivating S. aureus bacteria at micromolar concentrations. Complex 2, containing two phenanthrolines and a pyridine–pyrazole ligand, displays the highest potential for aPDT due to its optimized ligand structure, which enhances its physicochemical and optical properties and singlet oxygen production. It penetrates the bacterial cytoplasm and damages genomic DNA, efficiently neutralizing both Gram-positive and Gram-negative strains, as well as Candida albicans yeasts to a lesser extent. Meanwhile, it shows no toxicity toward human fibroblasts within therapeutic dose ranges. By bridging the gap between molecular structure and biological function, these results establish novel design criteria for choosing ligands to develop effective, selective Ru(II) aPDT agents., info:eu-repo/semantics/publishedVersion
Docta Complutense
Publicación Artículo científico (JournalArticle)

Cellular stress responses as modulators of drug cytotoxicity in pharmacotherapy of glioblastoma

  • Kusaczuk, Magdalena
  • Tovar Ambel, Elena
  • Naumowicz, Monika
  • Velasco Díez, Guillermo
Despite the extensive efforts to find effective therapeutic strategies, glioblastoma (GBM) remains a therapeutic challenge with dismal prognosis of survival. Over the last decade the role of stress responses in GBM therapy has gained a great deal of attention, since depending on the duration and intensity of these cellular programs they can be cytoprotective or promote cancer cell death. As such, initiation of the UPR, autophagy or oxidative stress may either impede or facilitate drug-mediated cell killing. In this review, we summarize the mechanisms that regulate ER stress, autophagy, and oxidative stress during GBM development and progression to later discuss the involvement of these stress pathways in the response to different treatments. We also discuss how a precise understanding of the molecular mechanisms regulating stress responses evoked by different pharmacological agents could decisively contribute to the design of novel and more effective combinational treatments against brain malignancies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer

  • Hermanova, Ivana
  • Zúñiga-García, Patricia
  • Caro-Maldonado, Alfredo|||0000-0002-5431-7949
  • Fernandez-Ruiz, Sonia
  • Salvador Velez, Fernando Maria|||0000-0002-0546-1354
  • Martín-Martín, Natalia|||0000-0002-2527-429X
  • Zabala-Letona, Amaia
  • Nuñez-Olle, Marc|||0000-0002-3593-2591
  • Torrano, Verónica
  • Camacho, Laura
  • Lizcano de Vega, José Miguel|||0000-0002-3154-5383
  • Talamillo, Ana
  • Carreira, Suzanne|||0000-0002-5077-5379
  • Gurel, Bora|||0000-0002-5018-8078
  • Cortazar, Ana Rosa|||0000-0002-7082-5695
  • Guiu, Marc|||0000-0002-7083-986X
  • López, Jose I.|||0000-0003-0842-5348
  • Martinez-Romero, Anabel
  • Astobiza, Ianire|||0000-0002-7142-7066
  • Valcarcel, Lorea|||0000-0002-7309-9924
  • Lorente, Mar|||0000-0003-0982-0956
  • Arruabarrena-Aristorena, Amaia|||0000-0002-1636-3944
  • Velasco, Guillermo|||0000-0002-1994-2386
  • Gomez Muñoz, Antonio|||0000-0002-2539-016X
  • Suárez-Cabrera, Cristian|||0000-0003-1897-1596
  • Lodewijk, Iris
  • Flores, Juana M.|||0000-0002-7995-4426
  • Sutherland, James D.|||0000-0003-3229-793X
  • Barrio, Rosa|||0000-0002-9663-0669
  • de Bono, Johann S.|||0000-0002-2034-595X
  • Paramio, Jesús M.|||0000-0001-7520-3177
  • Trka, Jan|||0000-0002-9527-8608
  • Graupera, Mariona|||0000-0003-4608-4185
  • Gomis, Roger R.|||0000-0001-6473-2858
  • Carracedo, Arkaitz|||0000-0001-5957-1260
This study unravels an unprecedented murine model of lethal metastatic prostate cancer, based on the combined deletion of Pten and Lkb1. Importantly, minimal activity of LKB1 is sufficient to hamper prostate cancer cell aggressiveness, thus redefining the relationship between gene dosage and tumor suppression. Gene dosage is a key defining factor to understand cancer pathogenesis and progression, which requires the development of experimental models that aid better deconstruction of the disease. Here, we model an aggressive form of prostate cancer and show the unconventional association of LKB1 dosage to prostate tumorigenesis. Whereas loss of Lkb1 alone in the murine prostate epithelium was inconsequential for tumorigenesis, its combination with an oncogenic insult, illustrated by Pten heterozygosity, elicited lethal metastatic prostate cancer. Despite the low frequency of LKB1 deletion in patients, this event was significantly enriched in lung metastasis. Modeling the role of LKB1 in cellular systems revealed that the residual activity retained in a reported kinase-dead form, LKB1 K78I, was sufficient to hamper tumor aggressiveness and metastatic dissemination. Our data suggest that prostate cells can function normally with low activity of LKB1, whereas its complete absence influences prostate cancer pathogenesis and dissemination.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The comparative responsiveness of Hospital Universitario Princesa Index and other composite indices for assessing rheumatoid arthritis activity

  • González-Álvaro, Isidoro
  • Castrejón, Isabel
  • Carmona, Loreto
  • Casado, Enrique|||0000-0001-8839-6430
  • García Gómez, M. C.
  • Gómez Centeno, E.
  • Gómez Vaquero, Carmen
  • Gratacós, Jordi|||0000-0003-4007-4103
  • Larrosa Padro, M.
  • Sanmartí, Raimon|||0000-0002-8864-3806
  • Tena Marsá, X.
  • Valls, M.
  • Diaz-Torne, Cesar|||0000-0001-6275-7699
  • Juanola, Xavier|||0000-0001-5998-6300
  • Laiz, Ana|||0000-0002-2820-4801
To evaluate the responsiveness in terms of correlation of the Hospital Universitario La Princesa Index (HUPI) comparatively to the traditional composite indices used to assess disease activity in rheumatoid arthritis (RA), and to compare the performance of HUPI-based response criteria with that of the EULAR response criteria. Secondary data analysis from the following studies: ACT-RAY (clinical trial), PROAR (early RA cohort) and EMECAR (pre-biologic era long term RA cohort). Responsiveness was evaluated by: 1) comparing change from baseline (Δ) of HUPI with Δ in other scores by calculating correlation coefficients; 2) calculating standardised effect sizes. The accuracy of response by HUPI and by EULAR criteria was analyzed using linear regressions in which the dependent variable was change in global assessment by physician (ΔGDA-Phy). ΔHUPI correlation with change in all other indices ranged from 0.387 to 0.791); HUPI's standardized effect size was larger than those from the other indices in each database used. In ACT-RAY, depending on visit, between 65 and 80% of patients were equally classified by HUPI and EULAR response criteria. However, HUPI criteria were slightly more stringent, with higher percentage of patients classified as non-responder, especially at early visits. HUPI response criteria showed a slightly higher accuracy than EULAR response criteria when using ΔGDA-Phy as gold standard. HUPI shows good responsiveness in terms of correlation in each studied scenario (clinical trial, early RA cohort, and established RA cohort). Response criteria by HUPI seem more stringent than EULAR's.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Metal-Organic Framework Incorporating Eight Different Size Rare-Earth Metal Elements, Toward Multifunctionality À La Carte

  • Li, Zhen|||0000-0002-8497-7497
  • Li, Xiao-Bao
  • Light, Mark E.|||0000-0002-0585-0843
  • Carrillo, Anna E.
  • Arauzo, Ana|||0000-0002-5999-341X
  • Valvidares, Manuel|||0000-0003-4895-8114
  • Roscini, Claudio|||0000-0002-0157-8934
  • Teixidor, Francesc|||0000-0002-3010-2417
  • Viñas, Clara|||0000-0001-5000-0277
  • Gándara, Felipe|||0000-0002-1671-6260
  • Bartolome, Elena|||0000-0001-5108-0977
  • Giner Planas, José|||0000-0002-1648-2169
Multi-metallic multivariate (MTV) rare earth (RE) metal-organic frameworks (MOFs) are of interest for the development of multifunctional materials, however examples with more than three RE cations are rare and obstructed by compositional segregation during synthesis. Herein, this work demonstrates the synthesis of a multi-metallic MTV RE MOF incorporating two, four, six, or eight different RE ions with different sizes and in nearly equimolar amounts and no compositional segregation. The MOFs are formed by a combination of RE cations (La, Ce, Eu, Gd, Tb, Dy, Y, and Yb) and a 1,7-di(4-carboxyphenyl)-1,7-dicarba-closo-dodecaborane (mCB-L) linker. The steric bulkiness and acidity of mCB-L is crucial for the incorporation of different size RE ions into the MOF structure. Demonstration of the incorporation of all RE cations is performed via compositional and structural characterization. The more complex MTV MOF, including all eight RE ions (mCB-8RE), are also characterized using optical, thermal, and magnetic techniques. Element-selective X-ray absorption spectroscopy and X-ray Magnetic Circular Dichroism measurements allow us to characterize spectroscopically each of the eight RE ions and determine their magnetic moments. This work paves the way for the investigation of MTV MOFs with the possibility to combine RE ions à la carte for diverse applications.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Rationalizing the carborane versus phenyl-driven luminescence in related dicarboxylic ligands and their antenna effect for their Eu3+ and Tb3+ metal-organic frameworks, a combined experimental and computational study

  • Li, Zhen|||0000-0002-8497-7497
  • Roscini, Claudio|||0000-0002-0157-8934
  • Núñez, Rosario|||0000-0003-4582-5148
  • Teixidor, Francesc|||0000-0002-3010-2417
  • Viñas, Clara|||0000-0001-5000-0277
  • Ruiz, Eliseo|||0000-0001-9097-8499
  • Giner Planas, José|||0000-0002-1648-2169
Replacement of a phenyl moiety by a carborane in 1,3-di(4-carboxyphenyl) derivatives has a pronounced effect on the photophysical properties of the compounds themselves and their corresponding Eu and Tb metal organic frameworks. Herein, we demonstrate that while the luminescence of the carborane-derivative 1,7-di(4-carboxyphenyl)-1,7-dicarba-closo-dodecaborane (mCB-L) is negligible in the solid state (0.3%), the corresponding phenyl-derivative [1,1' : 3',1''-terphenyl]-4,4''-dicarboxylic] (TDCA) is highly luminescent (quantum yield of 47.8%). However, the latter one is a much worse antenna for sensitizing Eu and Tb cations than the former one. Based on our previous studies where mCB-L behaves as a good antenna for these two lanthanides, we have now comparatively studied the optical properties of mCB-L and TDCA and their efficiency as sensitizers for Eu and Tb cations, in the solid state at room temperature. STEOM-DLPNO-CCSD calculations revealed a larger energy difference between the singlet S and the lowest conical intersection (CI) points for TDCA (33.0 kcal mol) than that for mCB-L (18.4 kcal mol), explaining the observed different luminescence properties of these two compounds. Contrary to the carborane derivative, TDCA exhibits a more distorted structure at the CI point. TDCA-Eu and TDCA-Tb MOFs have been synthesized and characterized by infrared spectroscopy (IR) and powder X-ray diffraction (PXRD). The optical properties of TDCA-Eu and TDCA-Tb MOFs were investigated, and both MOFs displayed luminescence in the visible region with characteristic emission bands attributed to Eu and Tb transitions, respectively. However, the quantum yields for TDCA-Ln (Eu, 11.1%; Tb, 4.8%) were found to be much lower than those of carborane-based MOFs (Eu, 20.5%; Tb, 49.8%), indicating that the TDCA ligand is a less efficient light-absorbing sensitizer for Eu and Tb ions compared to the carborane-based ligand and may favor undesired back-energy transfer, as suggested by their faster decay times in comparison with the carborane counterparts. STEOM-DLPNO-CCSD calculations are used to analyze the changes in electron densities on photo-excitation from S to S and de-excitation from T to S, as well as the differences in the excited state energies for mCB-L, TDCA, and the hypothetical longer derivatives (mCB-L2 and QDCA). Our research, which combines experimental and computational methods, offers valuable data for optimizing the singlet and triplet energies, as well as their differences (gaps), by choosing between phenyl and carborane as the building scaffold for 1,3-di(4-carboxyphenyl) compounds. This demonstrates that using phenyl or m-carborane as the building scaffold leads to distinct luminescence properties.